Incyte (INCY) Given a $145.00 Price Target by Credit Suisse Group Analysts
INCY has been the topic of a number of other reports. JPMorgan Chase & Co. restated a buy rating on shares of Incyte in a report on Wednesday, October 25th. BidaskClub cut shares of Incyte from a sell rating to a strong sell rating in a report on Tuesday, January 16th. Cowen restated a buy rating on shares of Incyte in a report on Tuesday, December 5th. Royal Bank of Canada upgraded shares of Incyte from a sector perform rating to an outperform rating and set a $136.00 price target on the stock in a report on Tuesday, January 2nd. Finally, Deutsche Bank initiated coverage on shares of Incyte in a report on Tuesday, December 12th. They issued a hold rating and a $106.00 price target on the stock. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $142.94.
Incyte (NASDAQ INCY) opened at $88.17 on Wednesday. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. The company has a market cap of $18,577.61, a PE ratio of -110.21 and a beta of 0.59. Incyte has a 1-year low of $80.85 and a 1-year high of $153.15.
Hedge funds have recently added to or reduced their stakes in the business. Financial Gravity Companies Inc. purchased a new stake in shares of Incyte during the fourth quarter valued at about $120,000. Private Advisor Group LLC purchased a new position in shares of Incyte in the 3rd quarter valued at approximately $203,000. Advantage Investment Management LLC raised its position in shares of Incyte by 1,233.3% in the 4th quarter. Advantage Investment Management LLC now owns 2,000 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1,850 shares during the last quarter. Caxton Associates LP purchased a new position in shares of Incyte in the 3rd quarter valued at approximately $257,000. Finally, Mission Wealth Management LP purchased a new position in shares of Incyte in the 4th quarter valued at approximately $213,000. 90.02% of the stock is owned by institutional investors and hedge funds.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.